Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps he is taking to ensure an adequate supply of ADHD medication.

The Department has worked closely with industry stakeholders and, following extensive collaborative efforts, previous issues have been resolved, and all strengths of lisdexamfetamine, atomoxetine capsules, atomoxetine oral solution, guanfacine prolonged-release tablets, and methylphenidate prolonged-release tablets are now available. We are working to resolve a remaining issue for Equasym XL capsules, and anticipate that this issue to be resolved in August 2025.

We continue to support the NHS England ADHD taskforce, which brings together expertise from the National Health Service, education, and justice sectors to coordinate a system-wide response to rising demand. In collaboration with NHS England’s national attention deficit hyperactivity disorder (ADHD) data improvement plan, we are developing future growth forecasts to support improved demand planning. These forecasts will be shared with industry to help ensure a more responsive and sustainable supply of ADHD medicines. In parallel, we are also engaging with new suppliers for ADHD medicines to increase supply capacity and resilience.

The Department also maintains and regularly updates a list of currently available and unavailable ADHD products on the Specialist Pharmacy Service website. This resource supports prescribers and dispensers in making informed decisions with patients. The list is available at the following link:

www.sps.nhs.uk/articles/prescribing-available-medicines-to-treat-adhd